Magenta Therapeutics

Equities

MGTA

US55910K1088

Real-time Estimate Cboe BZX 09:58:35 2024-03-28 am EDT 5-day change 1st Jan Change
30.78 USD +0.57% Intraday chart for Magenta Therapeutics +12.92% +178.11%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index CI
Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction. CI
North American Morning Briefing : PCE Inflation -2- DJ
North American Morning Briefing : Nasdaq Futures -2- DJ
North American Morning Briefing : Treasury Yields Keep Pushing Higher DJ
North American Morning Briefing : Attention Turns -2- DJ
Magenta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Index CI
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Value Index CI
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Value Index CI
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Index CI
Magenta Therapeutics, Inc. Announces Resignation of Lisa Olson as Head of Research and Chief Scientific Officer CI
Magenta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
North American Morning Briefing : Hopes Build for -3- DJ
Transcript : Dianthus Therapeutics, Inc., Magenta Therapeutics, Inc. - M&A Call
Dianthus Therapeutics, Inc. entered into a definitive merger agreement to acquire Magenta Therapeutics, Inc. in a reverse merger transaction. CI
Magenta Therapeutics, Inc. Enters into Sublease Termination and Release Agreement with Novartis Institutes for Biomedical Research, Inc CI
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : CPI Print Takes -3- DJ
North American Morning Briefing : Stocks Seen on -2- DJ
HC Wainwright Initiates Magenta Therapeutics at Neutral MT
Magenta Therapeutics, Inc. Announces Management Changes CI
Magenta Therapeutics, Inc. Announces the Resignation of Jason Gardner, Chief Executive Officer CI
Rapid January Jobs Growth and Weak Tech Earnings Weigh on US Equity Futures MT
Top Premarket Gainers MT
Chart Magenta Therapeutics
More charts
Magenta Therapeutics, Inc. is a biotechnology company focused on improving stem cell transplantation. The Company is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases, and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. It is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. Its pipeline of stem cell transplant product candidates consists of MGTA-117, MGTA-145, CD45-ADC, and its research platform. The MGTA-117 program is designed to selectively deplete stem cells from patients prior to transplant.
Sector
-
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
  1. Stock
  2. Equities
  3. Stock Magenta Therapeutics - Nasdaq
  4. News Magenta Therapeutics
  5. Magenta Therapeutics : JPMorgan Cuts Magenta Therapeutics to Neutral From Overweight, Price Target to $7 From $16